J
Jan A. Burger
Researcher at University of Texas MD Anderson Cancer Center
Publications - 543
Citations - 33028
Jan A. Burger is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 83, co-authored 511 publications receiving 28306 citations. Previous affiliations of Jan A. Burger include University of Texas Health Science Center at Houston & University of Freiburg.
Papers
More filters
Journal ArticleDOI
STAT3-Activated GM-CSFRα Translocates to the Nucleus and Protects CLL Cells from Apoptosis
Ping Li,David J. Harris,Zhiming Liu,Uri Rozovski,Alessandra Ferrajoli,Yongtao Wang,Carlos E. Bueso-Ramos,Inbal Hazan-Halevy,Srdana Grgurevic,William G. Wierda,Jan A. Burger,Susan O'Brien,Stefan Faderl,Michael J. Keating,Zeev Estrov +14 more
TL;DR: It was determined that overexpression of GM-CSFRα protected MM1 cells from dexamethasone-induced apoptosis, and GM- CSFRα knockdown induced apoptosis in CLL cells, suggesting that GM-csFRα provides a ligand-independent survival advantage.
Journal ArticleDOI
Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy
Jeffrey A. Jones,Peter Hillmen,Steven Coutre,Constantine S. Tam,Richard R. Furman,Paul M. Barr,Stephen J. Schuster,Thomas J. Kipps,Ian W. Flinn,Ulrich Jaeger,Jan A. Burger,Mei Cheng,Dana Lee,Danelle F. James,John C. Byrd,Susan O'Brien +15 more
TL;DR: The concomitant use of anticoagulant or antiplatelet agent was common in 2 clinical trials of single-agent ibrutinib in patients with CLL and the pattern of use of these agents was characterized and bleeding adverse events (AEs) observed in 2 trials were described.
Journal ArticleDOI
Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
Uri Rozovski,David Harris,Ping Li,Zhiming Liu,Preetesh Jain,Alessandra Ferrajoli,Jan A. Burger,Phillip Thompson,Nitin Jain,William G. Wierda,Michael J. Keating,Zeev Estrov +11 more
TL;DR: It is shown that, in CLL cells, the B-cell receptor (BCR) inhibitor ibrutinib reduced LPL mRNA and protein levels and inhibited FFA metabolism in vitro and in patients from ibrUTinib-treated patients, F FA metabolism was reduced and eventually stopped.
Journal ArticleDOI
Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).
Farhad Ravandi,Deborah A. Thomas,Hagop M. Kantarjian,Stefan Faderl,Charles Koller,Devri L. Brown,Rebecca Garris,Gautam Borthakur,Jan A. Burger,Partow Kebriaei,Jeffrey L. Jorgensen,Dan Jones,Jorge E. Cortes,Susan O'Brien +13 more
TL;DR: The combination of the hyperCVAD regimen with dasatinib is feasible and can achieve early molecular remissions in patients with Ph+ ALL and CML-LB.
Journal ArticleDOI
Better Molecular Response to Imatinib for Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Carrying the b3a2 Transcript Compared to b2a2.
Arturo Vega-Ruiz,Hagop M. Kantarjian,Jenny Shan,William G. Wierda,Jan A. Burger,Srdan Verstovsek,Guillermo Garcia-Manero,Jorge E. Cortes +7 more
TL;DR: Transcript levels were significantly lower at 3, 6 and 12 months from start of therapy for pts with b3a2 compared to those with b2a2, which resulted in a significantly higher probability of achieving a major molecular remission (MMR) and complete Molecular remission (CMR; ie, undetectable transcript levels), and there was a trend for an improved transformation-free survival.